

**Fiscal Impact**  
2<sup>nd</sup> Session of the 57<sup>th</sup> Legislature

**Bill No.:**

**SB 734**

**Version:**

**INT**

**Author:**

**Sen. McCortney**

**Date:**

**03/02/2021**

**Fiscal Analysis**

SB 734 would task OMES with the duties of compiling a list of the 250 most costly prescription drugs each year. This compiled list would be shared with the Insurance Department who must limit the price of commercial plans offering those 250 drugs to a comparable rate of their purchase price in Canada. An analysis by NASHP using public data of the gross cost to prescription drug plans of the 25 most costly drugs shows an estimated savings of \$52 million. The gross costs used in this estimation do not reflect the overall net price paid for drugs as there are many unknown variables. Current contracts also do not allow for the level of price transparency needed to give a detailed analysis. However, the estimates do account for a national average of rebates received by commercial pharmacy plans.

**FY'22 Impact:** None - No estimated savings until FY'23

**Full Year Impact:** Approximately \$52m in savings to the State

Prepared by: NASHP and Senate Fiscal Staff